MetaVia Inc. Faces Delisting Concerns

Ticker: MTVA · Form: 8-K · Filed: May 30, 2025 · CIK: 1638287

Metavia INC. 8-K Filing Summary
FieldDetail
CompanyMetavia INC. (MTVA)
Form Type8-K
Filed DateMay 30, 2025
Risk Levelhigh
Sentimentbearish

Sentiment: bearish

Topics: delisting, listing-standards, corporate-actions

TL;DR

MetaVia's in trouble, might get delisted.

AI Summary

MetaVia Inc. filed an 8-K on May 30, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company, formerly known as NeuroBo Pharmaceuticals, Inc. and Gemphire Therapeutics Inc., is based in Cambridge, MA.

Why It Matters

This filing indicates potential issues with MetaVia Inc.'s continued listing on an exchange, which could significantly impact its stock value and trading liquidity.

Risk Assessment

Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a severe risk to investors.

Key Players & Entities

FAQ

What specific listing rule or standard has MetaVia Inc. failed to satisfy?

The filing does not specify the exact rule or standard that MetaVia Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy one has been issued.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on May 29, 2025.

What is MetaVia Inc.'s principal executive office address?

MetaVia Inc.'s principal executive office is located at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138.

What were MetaVia Inc.'s previous company names?

MetaVia Inc. was formerly known as NeuroBo Pharmaceuticals, Inc. and prior to that, Gemphire Therapeutics Inc.

What is the filing date of this 8-K report?

This 8-K report was filed on May 30, 2025.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 30, 2025 regarding MetaVia Inc. (MTVA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing